US 11,730,805 B2
Paramyxoviridae expression system
Veljko Nikolin, Hannover (DE); Alissa Benter, Hannover (DE); and Andreas Gallei, Wedemark (DE)
Assigned to Boehringer Ingelheim Vetmedica GmbH
Appl. No. 16/649,456
Filed by Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein (DE)
PCT Filed Sep. 20, 2018, PCT No. PCT/EP2018/075542
§ 371(c)(1), (2) Date Mar. 20, 2020,
PCT Pub. No. WO2019/057859, PCT Pub. Date Mar. 28, 2019.
Claims priority of application No. 17192791 (EP), filed on Sep. 23, 2017.
Prior Publication US 2020/0276298 A1, Sep. 3, 2020
Int. Cl. A61K 39/155 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/155 (2013.01) [C12N 15/86 (2013.01); A61K 2039/53 (2013.01); A61K 2039/552 (2013.01); C12N 2750/14034 (2013.01); C12N 2760/16034 (2013.01); C12N 2760/18421 (2013.01); C12N 2760/18434 (2013.01); C12N 2760/18443 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A Paramyxoviridae virus vector comprising an expression cassette inserted between the P gene and the M gene, wherein said expression cassette comprises
a first nucleotide sequence, wherein said first nucleotide sequence is a heterologous or exogenous nucleotide sequence of interest, and
a second nucleotide sequence flanking the 5′ end of the first nucleotide sequence, wherein said second nucleotide sequence is the 5′ non-coding region of an N gene of a Paramyxoviridae virus, and
a third nucleotide sequence flanking the 3′ end of the first nucleotide sequence, wherein said third nucleotide sequence comprises or consists of the 3′ non-coding region of an H gene of a Paramyxoviridae virus.